Bayer HealthCare Pharmaceuticals, Inc. said it will discontinue marketing of leuprolide acetate implant (Viadur), which is indicated for the treatment of advanced prostate cancer. Based on diminished market demand and growing manufacturing costs, the company has concluded that the product has limited long-term market viability. Bayer said the decision is not the result of safety or efficacy issues.
Bayer HealthCare Pharmaceuticals, Inc. said it will discontinue marketing of leuprolide acetate implant (Viadur), which is indicated for the treatment of advanced prostate cancer. Based on diminished market demand and growing manufacturing costs, the company has concluded that the product has limited long-term market viability. Bayer said the decision is not the result of safety or efficacy issues.
Bayer will fulfill orders until current supplies are depleted, expected by the end of April 2008. Alternative therapies are available for the palliative care of prostate cancer patients. Patients are being advised to discuss these options with their health care providers.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.